Mohamad Mohty, MD, PhD from Saint-Antoine Hospital, Paris, France discussing treatment options for relapsed and refractory myeloma at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Due it is current high prevalence in the research field the physician’s role is becoming harder as there is a wider choice of therapies. When choosing these therapies practitioners need to consider age, comorbidities, prior history, bone-marrow reserves, organ dysfunction, as well as disease features and manifestations. When putting these components together management and sequence of treatments becomes complex, however Prof Mohty is confident that on a case by case basis it is possible to identify the optimal treatment for a patient.
EHA 2016: What does a physician need to consider when treating relapsed or refractory myelomas?
